Ionis partner Roche reports Phase 3 data: sefaxersen cuts proteinuria in IgA nephropathy
FROM THE WIRE · FINANCE.YAHOO.COM
– Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups – – Sefaxersen inhibits complement factor B production…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 3 data for an investigational drug can support Ionis shares, given its stake in the program.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria versus placebo at 37 weeks.
- 02The treatment effect was consistent across all prespecified patient subgroups.
- 03The investigational drug is designed as a once-monthly subcutaneous injection for home self-administration.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Ionis Pharmaceuticals, Inc.42.86 USD+0.13%today -2.39%Positive Roche Holding AG60.45 USD+0.32%today +1.39%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets